Structure Therapeutics doses first patients in Phase 3 obesity program for aleniglipron

Structure Therapeutics said the first patients have been dosed in its Phase 3 ACCOMPLISH program, which consists of two trials testing aleniglipron, a once-daily oral GLP-1 receptor agonist.¹ ACCOMPLISH-1 will study the drug in obese or overweight adults who have a weight-related comorbidity and plans to enroll as many as 3,600 people, while ACCOMPLISH-2 will test it in obese or overweight adults with type 2 diabetes and aims for up to 1,100 participants.¹ Both trials are randomized, double-blind and placebo-controlled, comparing three maintenance doses of 45 mg, 90 mg or 180 mg against placebo, with patients starting at 2.5 mg and titrating up every four weeks.¹ The company said the two trials are intended to support global regulatory filings for aleniglipron in chronic weight management.¹

On other pipeline items, Structure said data from the 72-week ACCESS Open Label Extension trial, which is testing a titration regimen starting at 2.5 mg, are expected in the third quarter of 2026.¹ Additional readouts are due later in the year: a body composition trial measuring fat loss over 44 weeks, with data expected in the fourth quarter,¹ and a SWITCH trial examining transition from an injectable GLP-1 drug to oral aleniglipron, also due in the fourth quarter.¹ The company's amylin/calcitonin agonist candidate ACCG-2671 remains in a Phase 1 single ascending dose trial, with initial data and the start of a multiple ascending dose trial still on track for the third quarter.¹ A second amylin candidate, ACCG-3535, is set to begin Phase 1 testing in the fourth quarter.¹

Structure also appointed John Berrios as chief commercial officer, citing more than 25 years of commercial leadership experience in biopharma.¹

On financials, cash, cash equivalents and short-term investments totaled $1.3 billion as of June 30, 2026, down from $1.5 billion at the end of the first quarter.¹ The company said this is expected to fund operations and key clinical milestones through the end of 2028, excluding pre-commercialization costs such as commercial manufacturing.¹